Metioprim

Metioprim is a competitive inhibitor of bacterial Dihydrofolate reductase (DHFR) . Metioprim has inhibitory activity against anaerobic bacteria. Metioprim shows synergistic activity in combination with DDS (HY-B0688) against E. coli. and various mycobacteria[1][2].

Product Specifications

CAS Number

[68902-57-8]

UNSPSC

12352005

Target

Bacterial; Dihydrofolate reductase (DHFR)

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/metioprim.html

Solubility

10 mM in DMSO

Smiles

NC1=NC(N)=C(CC2=CC(OC)=C(C(OC)=C2)SC)C=N1

Molecular Formula

C14H18N4O2S

Molecular Weight

306.38

References & Citations

[1]Wüst J, et al. Activity of brodimoprim and metioprim alone and in combination with sulfonamides against anaerobic bacteria. Antimicrob Agents Chemother. 1983 Mar;23 (3) :490-2. |[2]Seydel JK, et al. Bacterial growth kinetics of Escherichia coli and mycobacteria in the presence of brodimoprim and metioprim alone and in combination with sulfamerazine and dapsone (VI) . Chemotherapy. 1983;29 (4) :249-61. |[3]Nielsen P, et al. Pharmacokinetics and metabolism of metioprim in pigs and goats. Pharmacol Toxicol. 1987 Nov;61 (5) :330-4.